TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Retrophin, Inc. (NASDAQ: RTRX) Investor Investigation Over Possible Securities Laws Violations Announced

  • Investors who purchased shares of Retrophin, Inc. (NASDAQ: RTRX), have certain options and should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
Retrophin Inc
Security
NASDAQ: RTRX

Summary

An investigation was announced concerning potential securities laws violations by Retrophin, Inc. in connection with certain financial statements.

The investigation by a law firm focuses on whether a series of statements by Retrophin, Inc. (NASDAQ: RTRX regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

San Diego, CA based Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Retrophin, Inc. reported that its annual Total Revenue rose from $133.59 million in 2016 to $154.93 million in 2017 and that its Net Loss increased from $47.9 million in 2016 to $59.73 million in 2017.

Shares of Retrophin, Inc. (NASDAQ: RTRX) closed on November 2, 2018 at $25.80 per share.

Start Monitoring Your Investments